Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF.
The effect of corticosteroid on the concentration of amyloid beta-peptide (Abeta) in human CSF obtained from 16 patients without dementia treated with prednisolone (> or =30 mg daily) was studied. The concentrations of Abetax-40 and Abetax-42 in CSF decreased after treatment was started (p < 0.002). A moderate- or high-dose regimen of prednisolone decreases Abeta production or increases Abeta degradation in the human brain and deserves further study in AD.
Tokuda
T
T
Third Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. ttokuda@gipac.shinshu-u.ac.jp
Oide
T
T
Tamaoka
A
A
Ishii
K
K
Matsuno
S
S
Ikeda
S
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid* / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D003389:Cranial Nerve Diseases / Q000134:cerebrospinal fluid*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology; D006111:Graves Disease / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid*; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011111:Polymyalgia Rheumatica / Q000134:cerebrospinal fluid; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000134:cerebrospinal fluid*; D011239:Prednisolone / Q000008:administration & dosage / Q000494:pharmacology*
D016229:Amyloid beta-Peptides; D005938:Glucocorticoids; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); D011239:Prednisolone